Description

Zoledronic acid-Farmex (zoledronic acid) concentrate for infusions 4 mg/5 ml. vial №1

Ingredients

Active ingredient: Zoledronic acid
Other ingredients: Mannitol, sodium citrate, water for injections.

Dosage

The recommended dose: 4 mg (5 ml) infused over at least 15 minutes every 6 months.

Indications

Zoledronic acid-Farmex is indicated for:
– Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
– Prevention of skeletal-related events in patients with advanced malignancies involving bone.

Contraindications

Do not use Zoledronic acid-Farmex if:
– Hypocalcemia is present.
– Hypersensitivity to zoledronic acid or any component of the product exists.

Directions

For intravenous infusion only.
The solution should be clear and colorless. Any unused portion should be discarded.

Scientific Evidence

Zoledronic acid-Farmex has demonstrated efficacy in:
– Reducing the risk of fractures in osteoporosis.
– Decreasing skeletal-related events in patients with bone metastases.

Additional Information

Pharmacological Effects:
Zoledronic acid is a bisphosphonate that inhibits bone resorption. It acts by binding to hydroxyapatite crystals in bone, inhibiting osteoclast activity.

Clinical Trials and Comparative Effectiveness:
Clinical trials have shown that zoledronic acid is more effective in preventing fractures compared to other bisphosphonates. A study by Black et al. (2007) demonstrated a significant reduction in vertebral fractures with zoledronic acid compared to placebo.

In conclusion, Zoledronic acid-Farmex is a potent medication for the treatment of osteoporosis and skeletal-related events in cancer patients. Its efficacy and safety profile are supported by robust scientific evidence and clinical trials, making it a valuable option in clinical practice.